[1] MICROMEDEX?[S] .Healthcare Series Vol. 124 quarter 2/2005 [2] ABRUZZO G K，FLATTERY AM，GILL C J，et al. Evaluation of the echinocandin antifungal MK-0991(L-743，872)： efficacies in mouse models of disseminated aspergillosis，candidiasis，and cryptococcosis[J]. Antimicrob Agents Chemother，1997，41(11)：2333-2338. [3] ABRUZZO G K，GILL C J，FLATTERY A M，et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice[J]. Antimicrob Agents Chemother，2000，44(9)：2310-2318. [4] HERNANDEZ S，SOPEZ-RIBOT J L，NAJVAR L K，et al. Caspofungin resistance in Candida albicans： correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis[J] . Antimicrob Agents Chemother，2004，48(4)：1382-1383. [5] VILLANUEVA A，GOTUZZO E，ARATHOON E G，et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis[J]. Am J Med，2002，113：294-299. [6] MORA-DUARTE J，BETTS R，ROTSTEIN C，et al. Comparison of caspofungin and amphotericin B for invasive candidiasis[J]. N Engl J Med，2002，347：2020-2029. [7] THOMAS J，WALSH M D，HEDY T，et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia[J]. N Engl J Med，2004，351(9)：1391-1402.